Abilify Class Action
McPhadden Samac Tuovi LLP (“MCST”) has commenced a proposed class action in respect of the Abilify and Abilify Maintena. The action has been brought in the Ontario Superior Court of Justice.
Abilify was first approved for use in Canada in 2009. It had previously been approved for use in other countries as early as 2002. In Canada, product monographs for drugs are required to identify possible adverse effects. It was not until the 2015 that the product monograph for Abilify contained any warning of the compulsive disorders pathological gambling and hypersexuality. For instance, the 2013 product monograph did not mention the phrase “compulsive disorders” or the words “gambling” or “hypersexuality” even once.
Meanwhile, in December 2012 the European Medicines Agency, the European equivalent of Health Canada, had noted the possibility of pathological gambling in its Abilify Assessment Report.
It is alleged in MCST’s Statement of Claim that Abilify can cause compulsive behaviours such as compulsive gambling and hyper-sexuality and that the makers and marketers of the drug failed to warn Canadians of those dangers.
Similar litigation has been commenced in the United States and is being actively pursued.
Those who suffered compulsive behaviours are encouraged to register with us and to provide information regarding their experiences with Abilify and, in particular, information regarding any compulsive behaviours experienced while on Abilify.
We are particularly interested in hearing from patients who did not suffer from compulsive behaviours before taking Abilify but who started to experience such behaviours while taking Abilify and whose compulsive behaviours ended after they stopped taking Abilify.
Your information is best provided to us by completing the questionnaire at the link below. Completing the questionnaire does not establish a retainer arrangement with our firm. We will consider being retained by individuals with meritorious claims.
CLICK HERE TO START